Please login to the form below

Not currently logged in
Email:
Password:

AMNOG – One Year On...

A review of the impact of new pricing and reimbursement arrangements in Germany

Once the first country in Europe to get innovative products thanks to its favourable pricing structure, Germany was a popular launch destination. But the introduction of AMNOG and the G-BA test has left many wondering if they would not be better off avoiding the country altogether Justus Dehnen, Head of Pricing & Reimbursement, IMS Consulting Group and Olaf Zweig, Principal, Booz & Co review the first year of the new arrangements in detail and provide their insights on the likely impact on pharma companies.


The expert panel includes

  • Justus Dehnen, Pricing and Market Access Leader, Germany
  • Olaf Zweig, Principal, Global Health Practice, Berlin

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Using service design to improve patients’ quality of life
Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen....
Marketing Tree
Channel strategy and channeling your inner disrupter
Is this the answer to many of today's marketing challenges?...
Influencing behaviour change: Looking beyond market research
These strategies will give you the insight you need to influence behaviour change by creating a meaningful pharma customer journey....

Infographics